Zacks Investment Research on MSN

Vertex gears up to report Q1 earnings: What investors can expect

Vertex Pharmaceuticals VRTX is scheduled to report its first-quarter 2026 results on May 4, after market close. The Zacks ...
Monthly Prescribing Reference

Alyftrek and Trikafta Now Approved for Broader Cystic Fibrosis Use

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...
Morning Overview on MSN

Gene therapy targets rare cystic fibrosis mutation affecting ~10%

For roughly one in ten people living with cystic fibrosis, the drugs that have transformed survival for most CF patients are ...
Seeking Alpha

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the ...
Nasdaq

Should You Buy Vertex Before Feb. 12?

Vertex saw its shares drop after its third-quarter earnings report in November. The biotech is looking to expand its portfolio into pain management and renal therapies. Vertex Pharmaceuticals (NASDAQ: ...
Healio

Cystic fibrosis triple therapy linked to less chronic respiratory therapy use

Please provide your email address to receive an email when new articles are posted on . Chronic respiratory therapies included inhaled antibiotics, hypertonic saline, dornase alfa and oral ...